AZD0022

AZD0022 is a selective and orally active KRASG12D inhibitor. AZD0022 inhibits KRAS pathway suppression in the GP2D xenograft model[1].

Product Specifications

CAS Number

[2958627-18-2]

UNSPSC

12352005

Target

Ras

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

98.36

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC1=C(C#C)C2=[C@]([C@]3=C(F)C(N=C(OC[C@]4(C[C@@H](F)C5)N5CCC4)N=C6N7C[C@H]8N[C@H](C=C8)C7)=C6C=C3F)C=C(N)C=C2C=C1

Molecular Formula

C34H30F4N6O

Molecular Weight

614.64

References & Citations

[1]Kevin Beaumont, et al. Abstract 841: The preclinical pharmacokinetics and pharmacodynamics of AZD0022: A potent, oral KRASG12D-selective agent exhibiting oral bioavailability and KRAS pathway suppression in the GP2D xenograft model. Cancer Res (2025) 85 (8_Supplement_1) : 841.